KR20200096584A - 도파민-b-하이드록실라제 억제제 - Google Patents
도파민-b-하이드록실라제 억제제 Download PDFInfo
- Publication number
- KR20200096584A KR20200096584A KR1020207019157A KR20207019157A KR20200096584A KR 20200096584 A KR20200096584 A KR 20200096584A KR 1020207019157 A KR1020207019157 A KR 1020207019157A KR 20207019157 A KR20207019157 A KR 20207019157A KR 20200096584 A KR20200096584 A KR 20200096584A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- pyrrolo
- imidazol
- thioxo
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N C1NCCOC1 Chemical compound C1NCCOC1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- PDEGGHIGVXNUJU-NNJIEVJOSA-N CC(C)(C)OC(N(C[C@@H](C1)c2cc(F)cc(F)c2)C1C(CC(N1CCOCC1)=O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)c2cc(F)cc(F)c2)C1C(CC(N1CCOCC1)=O)=O)=O PDEGGHIGVXNUJU-NNJIEVJOSA-N 0.000 description 1
- KUHOSEMTYZEEIO-JBZHPUCOSA-N CCOC(CC(C(C[C@H](C1)c2cc(F)cc(F)c2)N1C(OC(C)(C)C)=O)=O)=O Chemical compound CCOC(CC(C(C[C@H](C1)c2cc(F)cc(F)c2)N1C(OC(C)(C)C)=O)=O)=O KUHOSEMTYZEEIO-JBZHPUCOSA-N 0.000 description 1
- YLVRWCKJDDTYFN-WAYWQWQTSA-N CN(C)C(/C=C\N=C)=C Chemical compound CN(C)C(/C=C\N=C)=C YLVRWCKJDDTYFN-WAYWQWQTSA-N 0.000 description 1
- 0 CN(Cc1ccccc1)C(CC(C([C@]1C2)NC[C@]12c1cc(F)ccc1F)=O)=* Chemical compound CN(Cc1ccccc1)C(CC(C([C@]1C2)NC[C@]12c1cc(F)ccc1F)=O)=* 0.000 description 1
- ZUTUAZHSWKNKQW-CYBMUJFWSA-N CN(Cc1cnccc1)C(CC(N1)=C(C[C@H](C2)c(c(F)ccc3Cl)c3F)N2C1=S)=O Chemical compound CN(Cc1cnccc1)C(CC(N1)=C(C[C@H](C2)c(c(F)ccc3Cl)c3F)N2C1=S)=O ZUTUAZHSWKNKQW-CYBMUJFWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1720189.8 | 2017-12-04 | ||
| GBGB1720189.8A GB201720189D0 (en) | 2017-12-04 | 2017-12-04 | Dopamine-B-hydroxylase inhibitors |
| GB1804439.6 | 2018-03-20 | ||
| GBGB1804439.6A GB201804439D0 (en) | 2018-03-20 | 2018-03-20 | Dopamin-b-hydroxylase inhibitors |
| PCT/PT2018/050043 WO2019112457A1 (en) | 2017-12-04 | 2018-11-30 | Dopamine-β-hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200096584A true KR20200096584A (ko) | 2020-08-12 |
Family
ID=65012066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207019157A Withdrawn KR20200096584A (ko) | 2017-12-04 | 2018-11-30 | 도파민-b-하이드록실라제 억제제 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11434242B2 (https=) |
| EP (1) | EP3720856A1 (https=) |
| JP (1) | JP7167155B2 (https=) |
| KR (1) | KR20200096584A (https=) |
| CN (1) | CN111479812A (https=) |
| AU (1) | AU2018379646A1 (https=) |
| BR (1) | BR112020010216A2 (https=) |
| CA (1) | CA3082337A1 (https=) |
| CL (1) | CL2020001461A1 (https=) |
| IL (1) | IL274550B2 (https=) |
| MX (1) | MX2020005864A (https=) |
| PH (1) | PH12020500542A1 (https=) |
| RU (1) | RU2020121820A (https=) |
| SG (1) | SG11202004231YA (https=) |
| TW (1) | TW201925193A (https=) |
| WO (1) | WO2019112457A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111479812A (zh) | 2017-12-04 | 2020-07-31 | 巴尔-波特拉及康邦亚股份有限公司 | 多巴胺-b-羟化酶抑制剂 |
| GB201908044D0 (en) | 2019-06-05 | 2019-07-17 | Bial Portela & Ca Sa | Dopamine-B-Hydroxylase inhibitors |
| US20250122171A1 (en) * | 2023-09-20 | 2025-04-17 | Deep Apple Therapeutics, Inc. | Substituted Amine Compounds, Compositions and Methods of Use |
| CN120383599A (zh) * | 2024-01-29 | 2025-07-29 | 上海深势唯思科技有限责任公司 | 芳基杂环类Kv1.3抑制剂及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647790A (en) | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
| FR2449689A1 (fr) | 1979-02-20 | 1980-09-19 | Logeais Labor Jacques | Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique |
| US4628059A (en) | 1985-10-31 | 1986-12-09 | Smithklein Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
| WO1995029165A2 (en) | 1994-04-26 | 1995-11-02 | Syntex (U.S.A.) Inc. | Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors |
| US6482982B1 (en) | 2001-03-09 | 2002-11-19 | University Of Sciences Of Philadelphia | Halogenated antituberculosis agents |
| IL143379A (en) * | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
| US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| WO2008085008A1 (en) | 2007-01-11 | 2008-07-17 | Mogam Biotechnology Research Institute | T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases |
| GB0708818D0 (en) * | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| JP2010534676A (ja) | 2007-07-23 | 2010-11-11 | シノシア・セラピューティクス | 心的外傷後ストレス障害の治療 |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
| CN111479812A (zh) | 2017-12-04 | 2020-07-31 | 巴尔-波特拉及康邦亚股份有限公司 | 多巴胺-b-羟化酶抑制剂 |
-
2018
- 2018-11-30 CN CN201880080871.5A patent/CN111479812A/zh active Pending
- 2018-11-30 SG SG11202004231YA patent/SG11202004231YA/en unknown
- 2018-11-30 CA CA3082337A patent/CA3082337A1/en active Pending
- 2018-11-30 KR KR1020207019157A patent/KR20200096584A/ko not_active Withdrawn
- 2018-11-30 RU RU2020121820A patent/RU2020121820A/ru unknown
- 2018-11-30 BR BR112020010216-4A patent/BR112020010216A2/pt not_active IP Right Cessation
- 2018-11-30 WO PCT/PT2018/050043 patent/WO2019112457A1/en not_active Ceased
- 2018-11-30 EP EP18833340.5A patent/EP3720856A1/en not_active Withdrawn
- 2018-11-30 MX MX2020005864A patent/MX2020005864A/es unknown
- 2018-11-30 TW TW107143059A patent/TW201925193A/zh unknown
- 2018-11-30 JP JP2020530502A patent/JP7167155B2/ja active Active
- 2018-11-30 AU AU2018379646A patent/AU2018379646A1/en not_active Abandoned
- 2018-11-30 US US16/769,045 patent/US11434242B2/en active Active
-
2020
- 2020-05-10 IL IL274550A patent/IL274550B2/en unknown
- 2020-06-01 CL CL2020001461A patent/CL2020001461A1/es unknown
- 2020-06-02 PH PH12020500542A patent/PH12020500542A1/en unknown
-
2022
- 2022-09-01 US US17/901,007 patent/US20230138795A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL274550B2 (en) | 2023-06-01 |
| US11434242B2 (en) | 2022-09-06 |
| JP7167155B2 (ja) | 2022-11-08 |
| WO2019112457A1 (en) | 2019-06-13 |
| TW201925193A (zh) | 2019-07-01 |
| CN111479812A (zh) | 2020-07-31 |
| IL274550A (en) | 2020-06-30 |
| MX2020005864A (es) | 2020-09-09 |
| PH12020500542A1 (en) | 2021-01-25 |
| US20210171528A1 (en) | 2021-06-10 |
| SG11202004231YA (en) | 2020-06-29 |
| BR112020010216A2 (pt) | 2020-09-15 |
| JP2021505568A (ja) | 2021-02-18 |
| CA3082337A1 (en) | 2019-06-13 |
| CL2020001461A1 (es) | 2020-10-16 |
| AU2018379646A1 (en) | 2020-06-11 |
| US20230138795A1 (en) | 2023-05-04 |
| RU2020121820A (ru) | 2022-01-10 |
| EP3720856A1 (en) | 2020-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102776114B1 (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
| CN111601799B (zh) | 作为Il-17调节剂的稠合咪唑衍生物 | |
| US10077243B2 (en) | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | |
| RU2632870C2 (ru) | Трициклические гетероциклические соединения и ингибиторы jak | |
| KR102049534B1 (ko) | 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법 | |
| AU2012258618B2 (en) | Metabotropic glutamate receptors 5 modulators and methods of use thereof | |
| US20190135799A1 (en) | Heterocyclic compound | |
| AU2016282289A1 (en) | HPK1 inhibitors and methods of using same | |
| BR112015009168B1 (pt) | Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica | |
| US20230138795A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| AU2012258618A1 (en) | Metabotropic glutamate receptors 5 modulators and methods of use thereof | |
| KR20170129729A (ko) | 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체 | |
| JP2018516970A (ja) | ムスカリンｍ２受容体の正のアロステリックモジュレーター | |
| WO2023077070A1 (en) | Rxfp1 agonists | |
| CN104418842A (zh) | 取代的吲哚化合物及其使用方法和用途 | |
| TW202440529A (zh) | Ｎａｍｐｔ調節劑 | |
| KR20240165360A (ko) | 에모파밀 결합 단백질 억제제 및 이의 용도 | |
| JP2018507900A (ja) | （インダゾール−４−イル）ヘキサヒドロピロロピロロン及び使用方法 | |
| WO2003078441A1 (en) | Aminomethyl-substituted thiazolobenzimidazole derivative | |
| KR20190132703A (ko) | 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법 | |
| EA043978B1 (ru) | ИНГИБИТОРЫ Bcl-2 | |
| EA035237B1 (ru) | ПРОИЗВОДНЫЕ ГЕТЕРОЦИКЛИЛАЛКИНОВ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ 5-ГО ПОДТИПА (mGluR5) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |